Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. more
Time Frame | LLY | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.3% | -5.55% | -0.8% |
1-Month Return | -18.33% | -7.2% | 2.36% |
3-Month Return | -19.93% | -7.12% | 7.31% |
6-Month Return | -5.23% | -2.98% | 12.04% |
1-Year Return | 26.73% | 10.85% | 32.05% |
3-Year Return | 188.62% | 6.66% | 26.94% |
5-Year Return | 558.95% | 45.54% | 90.46% |
10-Year Return | 1008.44% | 109.88% | 191.06% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 22.32B | 24.54B | 28.32B | 28.54B | 34.12B | [{"date":"2019-12-31","value":65.41,"profit":true},{"date":"2020-12-31","value":71.91,"profit":true},{"date":"2021-12-31","value":82.99,"profit":true},{"date":"2022-12-31","value":83.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 4.72B | 5.48B | 7.31B | 6.63B | 6.58B | [{"date":"2019-12-31","value":64.56,"profit":true},{"date":"2020-12-31","value":74.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.66,"profit":true},{"date":"2023-12-31","value":89.92,"profit":true}] |
Gross Profit | 17.60B | 19.06B | 21.01B | 21.91B | 27.55B | [{"date":"2019-12-31","value":63.88,"profit":true},{"date":"2020-12-31","value":69.18,"profit":true},{"date":"2021-12-31","value":76.25,"profit":true},{"date":"2022-12-31","value":79.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 78.85% | 77.66% | 74.18% | 76.77% | 80.73% | [{"date":"2019-12-31","value":97.67,"profit":true},{"date":"2020-12-31","value":96.19,"profit":true},{"date":"2021-12-31","value":91.88,"profit":true},{"date":"2022-12-31","value":95.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 11.81B | 12.21B | 13.46B | 13.63B | 17.22B | [{"date":"2019-12-31","value":68.57,"profit":true},{"date":"2020-12-31","value":70.88,"profit":true},{"date":"2021-12-31","value":78.14,"profit":true},{"date":"2022-12-31","value":79.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 4.97B | 6.06B | 6.36B | 7.13B | 10.33B | [{"date":"2019-12-31","value":48.18,"profit":true},{"date":"2020-12-31","value":58.67,"profit":true},{"date":"2021-12-31","value":61.57,"profit":true},{"date":"2022-12-31","value":69.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (28.60M) | (307.50M) | (516.00M) | (2.12B) | (4.08B) | [{"date":"2019-12-31","value":-2860000000,"profit":false},{"date":"2020-12-31","value":-30750000000,"profit":false},{"date":"2021-12-31","value":-51600000000,"profit":false},{"date":"2022-12-31","value":-211570000000,"profit":false},{"date":"2023-12-31","value":-408310000000,"profit":false}] |
Pre-Tax Income | 5.27B | 7.23B | 6.16B | 6.81B | 6.55B | [{"date":"2019-12-31","value":72.84,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":85.14,"profit":true},{"date":"2022-12-31","value":94.14,"profit":true},{"date":"2023-12-31","value":90.66,"profit":true}] |
Income Taxes | 628.00M | 1.04B | 573.80M | 561.60M | 1.31B | [{"date":"2019-12-31","value":47.79,"profit":true},{"date":"2020-12-31","value":78.85,"profit":true},{"date":"2021-12-31","value":43.66,"profit":true},{"date":"2022-12-31","value":42.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | 4.64B | 6.19B | 5.58B | 6.24B | 5.24B | [{"date":"2019-12-31","value":74.27,"profit":true},{"date":"2020-12-31","value":99.18,"profit":true},{"date":"2021-12-31","value":89.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true}] |
Income From Continuous Operations | 4.64B | 6.19B | 5.58B | 6.24B | 5.24B | [{"date":"2019-12-31","value":74.27,"profit":true},{"date":"2020-12-31","value":99.18,"profit":true},{"date":"2021-12-31","value":89.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true}] |
Income From Discontinued Operations | 3.68B | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 4.64B | 6.19B | 5.58B | 6.24B | 5.24B | [{"date":"2019-12-31","value":74.27,"profit":true},{"date":"2020-12-31","value":99.18,"profit":true},{"date":"2021-12-31","value":89.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true}] |
EPS (Diluted) | 6.04 | 7.93 | 8.17 | 8.09 | 6.32 | [{"date":"2019-12-31","value":73.93,"profit":true},{"date":"2020-12-31","value":97.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.02,"profit":true},{"date":"2023-12-31","value":77.36,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
LLY | |
---|---|
Cash Ratio | 0.14 |
Current Ratio | 1.27 |
Quick Ratio | 0.97 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
LLY | |
---|---|
ROA (LTM) | 13.95% |
ROE (LTM) | 65.32% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
LLY | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.81 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.19 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
LLY | |
---|---|
Trailing PE | 84.72 |
Forward PE | 35.84 |
P/S (TTM) | 18.27 |
P/B | 54.12 |
Price/FCF | NM |
EV/R | 19.54 |
EV/Ebitda | 63.79 |
PEG | 0.77 |
Eli Lilly and Company (LLY) share price today is $746.2
Yes, Indians can buy shares of Eli Lilly and Company (LLY) on Vested. To buy Eli Lilly and Company from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LLY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Eli Lilly and Company (LLY) via the Vested app. You can start investing in Eli Lilly and Company (LLY) with a minimum investment of $1.
You can invest in shares of Eli Lilly and Company (LLY) via Vested in three simple steps:
The 52-week high price of Eli Lilly and Company (LLY) is $972.53. The 52-week low price of Eli Lilly and Company (LLY) is $558.93.
The price-to-earnings (P/E) ratio of Eli Lilly and Company (LLY) is 88.5289
The price-to-book (P/B) ratio of Eli Lilly and Company (LLY) is 54.12
The dividend yield of Eli Lilly and Company (LLY) is 0.64%
The market capitalization of Eli Lilly and Company (LLY) is $777.36B
The stock symbol (or ticker) of Eli Lilly and Company is LLY